Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

SRT1720 HCl

Act 1001645-58-4 N-[2-[3-(Piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide, hydrochloride
Catalog No. ABIN7233295
  • Application
    Activation (Act)
    Purpose
    SIRT1 activator
    Characteristics
    Sirtuin1 (SIRT1) activator, EC1.5 = 0.16 μM, that reduces glucose levels and hyperinsulinemia in mouse and rat models of obesity. SRT1720 represses expression of circadian clock genes in vitro and in vivo. It inhibits vascular inflammation caused by angiotensin II-induced atherosclerosis and reverses abnormal mitochondrial function in primary neurons exposed to 20-HETE. Ameliorates hypoxic injury in pancreatic β-cells, and enhances ferroptosis in head and neck cancer cells.
    Purity
    >98 %
    Chemical Name
    N-[2-[3-(Piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide, hydrochloride
    Formula
    C25H23N7OS•HCl
    Solubility
    Soluble in DMSO (up to at least 25 mg/ml)
  • Restrictions
    For Research Use only
  • Format
    Powder
    Storage
    -20 °C
  • Background
    SIRT 1933,Redox,Epigenetics,Apoptosis inhibitor,Mitochondrial function,Protein deacetylase,Oxidative stress,Cell death,Circadian rhythm,Diabetes,Kidney disease,Atherosclerosis,Inflammation,Posttranslational modification,Obesity,Chromatin
    Molecular Weight
    506.0
    CAS-No
    1001645-58-4
You are here:
Support